Literature DB >> 2752996

Motor speed is a contaminating factor in evaluating the "cognitive" effects of phenytoin.

C B Dodrill1, N R Temkin.   

Abstract

Many studies suggestive of adverse effects of phenytoin (PHT) on mental abilities have used testing procedures which have timed or motor speed elements. Therefore, to what degree the motor speed element alone may have resulted in attributing adverse higher level intellectual or cognitive effects to PHT instead of the identified construct to be measured (e.g., memory, abstraction, decision making) is not clear. To help distinguish "motor" effects from these more complex "cognitive" effects, neuropsychological data on 70 adult PHT monotherapy patients were reanalyzed. Initially, a series of statistically significant differences favored the low serum level group over the high serum level group in neuropsychologic performance. However, when a simple measure of motor speed (Finger Tapping Test) was covaried out, all statistically significant differences between the groups disappeared. Thus, losses in cognitive abilities could not be associated with PHT even though markedly elevated blood levels had been achieved.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2752996     DOI: 10.1111/j.1528-1157.1989.tb05325.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  3 in total

1.  Cognitive Adverse Effects of Antiepileptic Drugs : Incidence, Mechanisms and Therapeutic Implications.

Authors:  R Kälviäinen; M Äikiä; P J Riekkinen
Journal:  CNS Drugs       Date:  1996-05       Impact factor: 5.749

2.  Effects of vigabatrin on partial seizures and cognitive function.

Authors:  R A Grünewald; P J Thompson; R Corcoran; Z Corden; G D Jackson; J S Duncan
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-09       Impact factor: 10.154

3.  Age-accelerated psychomotor slowing in temporal lobe epilepsy.

Authors:  Connie Sung; Jana E Jones; Daren C Jackson; Yui Chung Chan; Fong Chan; Michael Seidenberg; Bruce P Hermann
Journal:  Epilepsy Res       Date:  2012-09-16       Impact factor: 3.045

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.